MLYS•benzinga•
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
Summary
Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood pressure reductions and a strong safety profile.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga